Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

3(75.0%)

N/A

1(25.0%)

4Total

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07419373Phase 2Recruiting

ARN-75039 Lassa Fever Treatment in West Africa

Role: collaborator

NCT06212336Phase 2Recruiting

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Role: collaborator

NCT05044689Recruiting

Case Control Study to Identify Modifiable Risk Factors for Colorectal and Breast Cancer in Nigeria

Role: collaborator

NCT03655561Active Not Recruiting

Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Role: collaborator

NCT04907682Phase 2Completed

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Role: collaborator

NCT03944317Not ApplicableUnknown

Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP)

Role: lead

NCT03185637Completed

Children's Surgery in Sub-Saharan Africa

Role: collaborator

All 7 trials loaded